# US 10,307,358 B2 · Oral composition > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,307,358 B2 - Document ID: US10307358B2 - Status: Granted - Kind: B2 - Application number: 15/108,445 - Filed: 2013-12-27 - Published: 2016-11-10 - Granted: 2019-06-04 - Earliest claimed: 2013-12-27 - Assignees: Kao Corporation - Applicants: Kao Corporation - Inventors: Aya Ogihara; Morihide Itano - Web page: https://patentgrep.com/patent/US10307358B2 ## CPC - A61K 8/604: {Alkylpolyglycosides; Derivatives thereof, e.g. esters} - A61K 8/416: {Quaternary ammonium compounds (A61K8/35 takes precedence)} - A61K 8/43: Guanidines - A61K 8/4926: {having six membered rings} - A61K 8/60: Sugars; Derivatives thereof - A61K 8/922: {of vegetable origin} - A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration} - A61K 9/08: Solutions {(composition of solutions A61K47/00)} - A61K 31/4425: Pyridinium derivatives, e.g. pralidoxime, pyridostigmine - A61K 31/7028: Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages - A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers - A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters - A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin - A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone} - A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14) - A61Q 11/00: Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses - C07H 15/04: attached to an oxygen atom of the saccharide radical - A61K 2800/592: Mixtures of compounds complementing their respective functions - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS - C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13) ## Abstract The present invention relates to an oral composition having an enhanced solubility of an alkyl galactoside while holding an inhibiting effect on coaggregation of the alkyl galactoside well. The present invention provides an oral composition comprising the following components: (A) 0.001 mass % or more and 1 mass % or less of a compound represented by the following formula (I): wherein R is an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G is a galactose residue, E is a hydrogen atom or a methyl group, m is an integer of 0 to 200, and n is an integer of 1 to 30; (B) 0.001 mass % or more and 0.1 mass % or less of a cationic bactericide; and (C) 35 mass % or more of water. ## Claims ### Claim 1 An oral composition comprising the following components (A), (B), (C) and (D): (A) 0.01 mass % to 0.5 mass % of a compound represented by the following formula (I): wherein R represents an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G represents a galactose residue, E represents a hydrogen atom or a methyl group, m is 0, and n represents an integer of 1 to 3; (B) 0.001 mass % to 0.1 mass % of a cationic bactericide selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate and chlorhexidine hydrochloride; (C) 35 mass % or more of water; and (D) 0.1 mass % to 1.5 mass % of a nonionic surfactant, wherein, in the oral composition, the solubility of the compound represented by formula (I) is enhanced as compared to its solubility in a second composition that is the same as the oral composition except that the second composition lacks component (B), the cationic bactericide and wherein (A)/(B), the mass ratio of the content of component (A) to the content of component (B), is 0.1 to 100. ### Claim 2 (depends on 1) The oral composition according to claim 1, comprising 0.2 to 1.2 mass % of component (D). ### Claim 3 (depends on 1) The oral composition according to claim 1, wherein (A)/(B), the mass ratio of the content of component (A) to the content of component (B), is 2 to 100. ### Claim 4 (depends on 2) The oral composition according to claim 2, wherein {(A)+(B)}/(D), the mass ratio of the total content of component (A) and component (B) to the content of component (D), is 0.02 to 2. ### Claim 5 (depends on 1) The oral composition according to claim 1, wherein the composition comprises 0.008 mass % to 0.06 mass % of component (B). ### Claim 6 (depends on 2) The oral composition according to claim 2, wherein component (D) is one or two or more selected from the group consisting of a polyoxyethylene hydrogenated castor oil, a polyoxyethylene sorbitan fatty acid ester, a polyglycerol fatty acid ester, a polyoxyethylene alkyl ether, an alkyl polyglucoside, and a sucrose fatty acid ester. ### Claim 7 (depends on 1) The oral composition according to claim 1, wherein the oral composition is a liquid oral composition. ### Claim 8 A method for inhibiting plaque accumulation, comprising applying, to the oral cavity, an oral composition comprising the following components (A), (B), (C) and (D): (A) 0.01 mass % to 0.5 mass % of a compound represented by the following formula (I): wherein R represents an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G represents a galactose residue, E represents a hydrogen atom or a methyl group, m is 0, and n represents an integer of 1 to 3; (B) 0.001 mass % to 0.1 mass % of a cationic bactericide selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate and chlorhexidine hydrochloride; (C) 35 mass % or more of water; and (D) 0.1 mass % to 1.5 mass % of a nonionic surfactant, wherein, in the oral composition, the solubility of the compound represented by formula (I) is enhanced as compared to its solubility in a second composition that is the same as the oral composition except that the second composition lacks component (B), the cationic bactericide, and wherein (A)/(B), the mass ratio of the content of component (A) to the content of component (B), is 0.1 to 100. ### Claim 9 A method for inhibiting halitosis, comprising applying, to the oral cavity, an oral composition comprising the following components (A), (B), (C) and (D): (A) 0.01 mass % to 0.5 mass % of a compound represented by the following formula (I): wherein R represents an optionally substituted linear or branched alkyl group having 8 to 18 carbon atoms, G represents a galactose residue, E represents a hydrogen atom or a methyl group, m is 0, and n represents an integer of 1 to 3; (B) 0.001 mass % to 0.1 mass % of a cationic bactericide selected from the group consisting of cetylpyridinium chloride, benzethonium chloride, benzalkonium chloride, chlorhexidine gluconate and chlorhexidine hydrochloride; and (C) 35 mass % or more of water; and (D) 0.1 mass % to 1.5 mass % of a nonionic surfactant, wherein, in the oral composition, the solubility of the compound represented by formula (I) is enhanced as compared to its solubility in a second composition that is the same as the oral composition except that the second composition lacks component (B), the cationic bactericide, and wherein (A)/(B), the mass ratio of the content of component (A) to the content of component (B), is 0.1 to 100. ### Claim 10 (depends on 8) The method according to claim 8, wherein the composition comprises 0.2 mass % to 1.2 mass % of component (D). ### Claim 11 (depends on 8) The method according to claim 8, wherein the composition comprises 0.2 mass % to 1.2 mass % of component (D).